Parathyroid hormone is under clinical development by Takeda Pharmaceutical and currently in Phase III for Post Menopausal Osteoporosis. According to GlobalData, Phase III drugs for Post Menopausal Osteoporosis have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Parathyroid hormone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Parathyroid hormone overview
Parathyroid hormone (Preotact / Preotakt / Natpara / SHP-634 / TAK-834 / Natpar) is produced in Escherichia coli by recombinant DNA technology. It is formulated as powder for solution for injection for subcutaneous route of administration. It is indicated for the treatment of osteoporosis (a disease that makes bones fragile) in postmenopausal women who are at high risk of fractures. Parathyroid Hormone (SHP-634/Natpar) indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
It was under development for hypothyroidism in Japan. It was also under development for the treatment of postmenopausal women with osteoporosis in the U.S.
Takeda Pharmaceutical overview
Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China, India, and Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
For a complete picture of Parathyroid hormone’s drug-specific PTSR and LoA scores, buy the report here.